WallStreetZenWallStreetZen

NASDAQ: RIGL
Rigel Pharmaceuticals Inc Stock

$1.08-0.04 (-3.57%)
Updated Sep 29, 2023
RIGL Price
$1.08
Fair Value Price
$1.31
Market Cap
$188.31M
52 Week Low
$0.67
52 Week High
$2.04
P/E
-4.91x
P/B
-6.7x
P/S
1.77x
PEG
N/A
Dividend Yield
N/A
Revenue
$126.64M
Earnings
-$37.77M
Gross Margin
97.9%
Operating Margin
-25.88%
Profit Margin
-29.8%
Debt to Equity
-5.17
Operating Cash Flow
-$33M
Beta
1.27
Next Earnings
Nov 1, 2023
Ex-Dividend
N/A
Next Dividend
N/A

RIGL Overview

Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.

Zen Score

Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how RIGL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

RIGL ($1.08) is undervalued by 17.69% relative to our estimate of its Fair Value price of $1.31 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
RIGL ($1.08) is not significantly undervalued (17.69%) relative to our estimate of its Fair Value price of $1.31 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
RIGL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more RIGL due diligence checks available for Premium users.

Be the first to know about important RIGL news, forecast changes, insider trades & much more!

RIGL News

Valuation

RIGL fair value

Fair Value of RIGL stock based on Discounted Cash Flow (DCF)
Price
$1.08
Fair Value
$1.31
Undervalued by
17.69%
RIGL ($1.08) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
RIGL ($1.08) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
RIGL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

RIGL price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-4.91x
Industry
13.67x
Market
12.37x

RIGL price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
-6.7x
Industry
5.09x

RIGL's financial health

Profit margin

Revenue
$26.9M
Net Income
-$6.6M
Profit Margin
-24.5%
RIGL's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
RIGL's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$117.1M
Liabilities
$145.2M
Debt to equity
-5.17
RIGL's short-term assets ($100.93M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RIGL's long-term liabilities ($101.18M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RIGL's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
RIGL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$5.9M
Investing
$3.0M
Financing
-$373.0k
RIGL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

RIGL vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
RIGL$188.31M-3.57%-4.91x-6.70x
SGMT$187.92M-2.87%N/A-0.95x
GOSS$187.69M+6.79%-0.38x-2.99x
IVVD$186.58M-3.95%-1.06x0.66x
OMER$183.54M0.00%4.49x8.95x

Rigel Pharmaceuticals Stock FAQ

What is Rigel Pharmaceuticals's quote symbol?

(NASDAQ: RIGL) Rigel Pharmaceuticals trades on the NASDAQ under the ticker symbol RIGL. Rigel Pharmaceuticals stock quotes can also be displayed as NASDAQ: RIGL.

If you're new to stock investing, here's how to buy Rigel Pharmaceuticals stock.

What is the 52 week high and low for Rigel Pharmaceuticals (NASDAQ: RIGL)?

(NASDAQ: RIGL) Rigel Pharmaceuticals's 52-week high was $2.04, and its 52-week low was $0.67. It is currently -47.06% from its 52-week high and 61.68% from its 52-week low.

How much is Rigel Pharmaceuticals stock worth today?

(NASDAQ: RIGL) Rigel Pharmaceuticals currently has 174,364,286 outstanding shares. With Rigel Pharmaceuticals stock trading at $1.08 per share, the total value of Rigel Pharmaceuticals stock (market capitalization) is $188.31M.

Rigel Pharmaceuticals stock was originally listed at a price of $63.99 in Nov 29, 2000. If you had invested in Rigel Pharmaceuticals stock at $63.99, your return over the last 22 years would have been -98.31%, for an annualized return of -16.93% (not including any dividends or dividend reinvestments).

How much is Rigel Pharmaceuticals's stock price per share?

(NASDAQ: RIGL) Rigel Pharmaceuticals stock price per share is $1.08 today (as of Sep 29, 2023).

What is Rigel Pharmaceuticals's Market Cap?

(NASDAQ: RIGL) Rigel Pharmaceuticals's market cap is $188.31M, as of Oct 1, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Rigel Pharmaceuticals's market cap is calculated by multiplying RIGL's current stock price of $1.08 by RIGL's total outstanding shares of 174,364,286.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.